Rhythm Pharmaceuticals Inc.
RYTMHeld by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase3 readout (Setmelanotide): Mar 2025. Short interest: 15.8% of float.
Held by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase3 readout (Setmelanotide): Mar 2025. Short interest: 15.8% of float.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)
10 specialist funds hold RYTM with a Phase 2 in 17 days for Setmelanotide (Prader-Willi Syndrome, Obesity, Hyperphagia)
+4 more upcoming catalysts
Position history (shares)
Commodore Capital (Atkinson/Kramarz) fully exited RYTM this quarter, liquidating its entire position ahead of a crowded but back-weighted catalyst runway — the nearest meaningful readout is the Phase 3 setmelanotide hypothalamic obesity data (March 2025), with the bulk of events stretching into 2026–2028. The exit is notable given 10 specialist funds remain holders, including RA Capital, Baker Bros., and Perceptive, suggesting Commodore is stepping away from a name with otherwise high institutional conviction — a divergence worth monitoring.
7 quarters
Feb 17, 2026
$1.8B
6 funds
May 15, 2026
$1.5B
7 funds
May 29, 2026
$218.8M
1 fund
Aug 14, 2026
$2.2B
8 funds
+804% total institutional value over 22 quarters
Short Shares
10.77M
Change
+4.5%
Days to Cover
16.3
% of Float
15.8%
Settlement
Sep 30, 2026
Short interest over 12 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
I appreciate the request, but I need to flag that the publication date listed (August 1, 2026) is in the future, which suggests this may be a fictional or hypothetical article. I cannot locate or verify this specific publication. If this is a real article you're referencing, I'd recommend providing the actual DOI or PubMed ID so I can access the accurate content. Alternatively, if you have the article text available, I'm happy to summarize it for investment purposes. For context on why this matters: Setmelanotide is Rhythm's lead MC4R agonist for rare genetic obesity disorders (IMCLA and POMC/PCSK1 deficiency), and any clinical data on its endocrine effects would be material to understanding patient outcomes, label expansion potential, and competitive positioning versus GLP-1 agonists in rare genetic indications.
# Investment Summary: Setmelanotide Safety Profile **Clinical Finding:** This 2026 systematic review documents the adverse event profile of setmelanotide (Imcivree), Rhythm's melanocortin-4 receptor agonist for rare genetic obesity, using integrated disproportionality analysis and meta-analysis to characterize safety signals across available clinical data. **Investor Implications:** A comprehensive safety assessment is critical for setmelanotide's commercial viability, as safety concerns could limit label expansion beyond its narrow rare disease indication (POMC/PCSK9/LEPR deficiency) and affect long-term patient compliance and reimbursement coverage. The timing (2026) suggests emerging real-world safety data that could either validate the risk-benefit profile for label extensions or constrain growth projections if new safety signals emerge requiring additional monitoring or contraindications.
# Investment Summary: Rhythm Pharmaceuticals (RYTM) Setmelanotide, RYTM's approved MC4R agonist for rare genetic obesity, demonstrates a novel mechanism in this study—interrupting ICAM-1/JIP1 binding at the blood-brain barrier to reverse diabetes-related cognitive dysfunction. This finding suggests potential label expansion beyond current rare genetic obesity indications into the larger diabetes comorbidity space, particularly for diabetic cognitive impairment, a condition lacking approved treatments. However, investors should note this mechanism differs from setmelanotide's primary weight-loss pathway, requiring separate clinical validation and regulatory approval to represent meaningful revenue opportunity.
# Investment Summary: RYTM Setmelanotide Formulation Research **Clinical/Commercial Relevance:** This research addresses pharmaceutical manufacturing optimization for setmelanotide, Rhythm's approved rare disease treatment, by investigating pH-dependent drug loading efficiency into PLGA microspheres—a long-acting injectable delivery platform. Successfully engineering improved formulations could enhance patient convenience through extended dosing intervals and potentially expand the addressable market by improving tolerability and compliance in POMC/PCSK1/PDYN pathway obesity patients. **Investor Takeaway:** The work suggests Rhythm is actively developing next-generation delivery systems beyond the current oral formulation, which could represent a meaningful commercial differentiator and provide lifecycle extension opportunities as patent expiration timelines approach.
# Investment Summary: Setmelanotide in Craniopharyngioma-Associated Obesity This real-world study demonstrates setmelanotide's safety and effectiveness in pediatric craniopharyngioma patients with severe obesity, expanding clinical evidence beyond the rare genetic obesity indications for which RYTM received FDA approval. The data supports potential label expansion or off-label adoption in this secondary indication, though craniopharyngioma-related obesity represents a modest market opportunity compared to RYTM's core genetic obesity franchise. Investors should monitor whether positive real-world findings translate into expanded clinical trials or reimbursement coverage, as this could modestly broaden the addressable patient population but is unlikely to materially impact revenue guidance without formal regulatory or payer actions.
Start free trial for share counts, dollar values & AI analysis
108 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: